A novel biological therapy (PC-01) for ocular surface regeneration
Ended Purchase Order Awarded
- Contract number
- FA864921P0155
- Awardee
-
Ocubio, LLC UEI GKSDH7WKL834
- Awarding agency
-
Air Force Research Laboratory
Air Force Materiel Command, Department of Defense
- Obligated
- $149,967
Award facts
- Contract value 100% obligated
- $149,967.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 335 offers Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Coconut Grove, FL 33133, USA
- Research
- STTR Phase I
Award details come from SAM.gov/FPDS.
About this award
The Department of the Air Force Materiel Command Research Laboratory awarded a STTR Phase I contract to Plasmacord, LLC, a small disadvantaged business, for the development of a novel biological therapy (PC-01) for ocular surface regeneration. The firm-fixed-price contract, valued at $149,967.00, has a completion date of July 15, 2021. The contract was set aside for small businesses.
Quick answers
Who was awarded contract FA864921P0155?
FA864921P0155 was awarded to Ocubio, LLC by Air Force Research Laboratory (Air Force Materiel Command) on January 14, 2021.
How much is contract FA864921P0155 worth?
The government has obligated $149,967 on FA864921P0155.
Was contract FA864921P0155 competed?
The extent of competition for FA864921P0155 was full and open competition after exclusion of sources. The government received 335 offers. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award